Shakil Ian's Form 4 filing
Augmedix, Inc. (AUGX) · filed Apr 15, 2024
- Accession no.
- 0001213900-24-033121
- Filed
- Apr 15, 2024
- Trade date
- Apr 12, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $74.7K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shakil IanCIK 0001826129 | Director, Officer (CHIEF STRATEGY OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 12, 2024 | Common Stock | MOption exerciseAcquired | +19,544 | $0.86 | +$16,807.84 | 22,544 | Direct | |
| Apr 12, 2024 | Common Stock | SSaleDisposed | −19,544 | $3.82F2 | −$74,658.08 | 3,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 12, 2024 | Common Stock | MOption exerciseDisposed | −19,544 | $0.00 | $0 | 456,449 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades ranging from $3.8000 to $3.9300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.